28-Mar-2024
No headlines found.
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 26-Mar 7:00 AM ET)
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
Globe Newswire (Mon, 11-Mar 7:00 AM ET)
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Mon, 26-Feb 4:06 PM ET)
Globe Newswire (Mon, 26-Feb 4:05 PM ET)
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 20-Feb 7:00 AM ET)
Globe Newswire (Mon, 5-Feb 7:00 AM ET)
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Fibrogen trades on the NASDAQ stock market under the symbol FGEN.
As of March 28, 2024, FGEN stock price declined to $2.35 with 1,287,158 million shares trading.
FGEN has a beta of 1.09, meaning it tends to be more sensitive to market movements. FGEN has a correlation of 0.00 to the broad based SPY ETF.
FGEN has a market cap of $232.11 million. This is considered a Small Cap stock.
Last quarter Fibrogen reported $27 million in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.15.
In the last 3 years, FGEN stock traded as high as $36.13 and as low as $.33.
The top ETF exchange traded funds that FGEN belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.
FGEN stock has underperformed the market in the last year with a return of -87.4%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in FGEN shares. However, FGEN has outperformed the market in the last 3 month and 2 week periods, returning +190.4% and +17.5%, while SPY returned +10.1% and +1.7%, respectively. This indicates FGEN has been having a stronger performance recently.
FGEN support price is $2.38 and resistance is $2.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FGEN stock will trade within this expected range on the day.